From August 18th 2026, GtoPdb will require users to register to use the website. Please see our blog post for more information.

mosunetuzumab   Click here for help

GtoPdb Ligand ID: 12298

Synonyms: BTCT4465A | CD20-TDB [7] | Lunsumio® | mosunetuzumab-axgb | RG-7828 | RO7030816
Approved drug
mosunetuzumab is an approved drug (EMA & FDA (2022))
Compound class: Antibody
Comment: Mosunetuzumab (BTCT4465A) is an anti-CD20(MS4A1)/CD3e bispecific antibody [7] that was developed by Roche/Genentech to eliminate CD20+ve B cell malignancies by recruiting and activating effector T cells [1,4-5].
Bioactivity Comments
Mosunetuzumab effectively kills patient-derived CLL B cells in vitro and in vivo [7].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD20 (membrane-spanning 4-domains, subfamily A, member 1) Hs Antibody Binding - - - 7
⤷ [7]
CD3e Hs Antibody Agonist - - - 7
⤷ [7]